1164PEfficacy of racotumomab or nimotuzumab vs docetaxel as second-line therapy for advanced non-small cell lung cancer patients. (23rd October 2018) - Hernandez, M; Neninger, E; Santiesteban, E; Camacho, K; Hernandez, N; Amador, R; Acosta, S; Gonzalez, Y; Jimenez, Y; Corella, M; Ortiz, R A; Bello, L; et al.